Is Actuate Therapeutics, Inc. Common stock (ACTU) overvalued? · $49.0M cap
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
This page asks whether Actuate Therapeutics, Inc. Common stock (ACTU) looks expensive on cached numbers — not a short thesis.
No cached income statement for ACTU, so there is no earnings base to call rich or cheap.
ACTU currently screens at market cap $49.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ACTU 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ACTU stock page for the full model, not this heading.
Not investment advice.